Tetra Bio-Pharma Inc.
OTCQB : TBPMF
TSX VENTURE : TBP

Tetra Bio-Pharma Inc.

April 03, 2018 13:55 ET

Tetra Bio-Pharma Names Guy Chamberland as Interim CEO

OTTAWA, ONTARIO--(Marketwired - April 3, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the appointment of Guy Chamberland, M.Sc., Ph.D., an accomplished drug developer, as interim Chief Executive Officer (CEO). This appointment is effective immediately.

Dr. Chamberland has been Chief Scientific Officer & Regulatory Affairs of Tetra since June 2016. He has over 23 years' experience in the development of new drugs in the pharmaceutical industry (Canada and USA). He worked more than 10 years as an executive in various biopharmaceutical companies and was a member of the investment committee of a venture capital fund for 7 years.

Tetra's former CEO, Bernard Fortier, left the corporation today thereby terminating his role as Chief Executive Officer and member of the Board of Directors.

"We are thankful for Bernard's contributions to Tetra's activities," stated André Rancourt, Chairman of the Board. "Guy's role as interim CEO will be a tremendous asset at this stage of Tetra's growth. He will maintain his role and responsibility as Chief Scientific Officer while ensuring the growth and strategic operations of the corporation."

Chamberland will serve as interim Chief Executive Officer while the Board of Directors conducts a search for a new Chief Executive Officer.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation's ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation's business plan; the success of the Rx Princeps product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation's public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Contact Information

  • Tetra Bio-Pharma Inc.
    Dr. Anne-Sophie Courtois, DVM
    Vice President, Marketing & Communications
    (438) 899-7575

    For investors information, please contact:
    investors@tetrabiopharma.com
    (438) 504-5784